Yesterday February 8th, the first patient at UZ Leuven was treated with Iscalimab. Safety and efficacy of CFZ533 on preservation of pancreatic β-cell function, will be evaluated in new onset type one diabetes, age 15-21. This trial is a collaboration between Novartis & INNODIA.